Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports

Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports Publisher Pubmed

Khoshnamrad N¹ ; Gheymati A¹ ; Jahangardrafsanjani Z^{1, 2}

Show Affiliations

1. Department of Clinical Pharmacy, Faculty of Pharmacy, Tehran, Iran
2. Breast Disease Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran

Source: Anti-Cancer Drugs Published:2022

Abstract

Pyoderma gangrenosum is a rare ulcerative dermatosis. It may be caused by some drugs, including small molecule tyrosine kinase inhibitors (TKIs). The aim of this study was to evaluate the reported evidence of pyoderma gangrenosum associated with the use of these drugs. A systematic electronic literature search of PubMed and Embase was conducted. In these databases, search terms describing pyoderma gangrenosum were combined with TKIs. Fifteen case reports (eight cases associated with sunitinib, two with imatinib, two with ibrutinib, one with gefitinib, one with pazopanib, and one with dabrafenib and trametinib) were identified over the 14 years. The average Naranjo score of these cases is 6.6, which indicates a probable adverse drug reaction. Pyoderma gangrenosum is a probable and reversible drug reaction associated with some TKIs. Detailed medical history can help to prompt diagnosis of drug-induced pyoderma gangrenosum. Clinicians should be aware of TKI-associated pyoderma gangrenosum when caring for the skin of oncologic patients undergoing therapy with kinase inhibitors. Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Style	Citing Format
MLA	Khoshnamrad N, Gheymati A, Jahangardrafsanjani Z. "Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports." Anti-Cancer Drugs, vol. 33, no. 1, 2022, pp. E1-E8.
APA	Khoshnamrad N, Gheymati A, Jahangardrafsanjani Z (2022). Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports. Anti-Cancer Drugs, 33(1), E1-E8.
Chicago	Khoshnamrad N, Gheymati A, Jahangardrafsanjani Z. "Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports." Anti-Cancer Drugs 33, no. 1 (2022): E1-E8.
Harvard	Khoshnamrad N, Gheymati A, Jahangardrafsanjani Z (2022) 'Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports', Anti-Cancer Drugs, 33(1), pp. E1-E8.
Vancouver	Khoshnamrad N, Gheymati A, Jahangardrafsanjani Z. Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports. Anti-Cancer Drugs. 2022;33(1):E1-E8.
BibTex	@article{ author = {Khoshnamrad N and Gheymati A and Jahangardrafsanjani Z}, title = {Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports}, journal = {Anti-Cancer Drugs}, volume = {33}, number = {1}, pages = {E1-E8}, year = {2022} }
RIS	TY - JOUR AU - Khoshnamrad N AU - Gheymati A AU - Jahangardrafsanjani Z TI - Tyrosine Kinase Inhibitors-Associated Pyoderma Gangrenosum, a Systematic Review of Published Case Reports JO - Anti-Cancer Drugs VL - 33 IS - 1 SP - E1 EP - E8 PY - 2022 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract